Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
May 21, 2020- Urgent care clinic study shows ID NOW test performance of ≥94.7% positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) compared to lab-based PCR reference tests- The Everett Clinic study shows 91.3% positive agreement and 100% negative agreement- Ongoing study of hospitalized and nursing home patients tested with late symptom onset shows ≥83.3% positive agreement and ≥96.5% negative agreement- Abbott's studies suggest ID NOW performs best in patients tested earlier post symptom onset- ID NOW delivers results in minutes rather than days and is helping reduce the spread of infection by detecting more positive patients faster than would otherwise be the case- May 21, 2020- Abbott's antibody test to be deployed as part of the UK Secretary of State for Health's initiative for highly-reliable, large-scale antibody testing- European-made blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR, as well as its Alinity™ i laboratory instruments- 800,000 Abbott tests have already been delivered to NHS laboratories across the UK- Test demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started
- May 12, 2020Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System- Alinity m is Abbott's new molecular lab system, which was approved by the U.S. FDA in March- The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours- Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization- This is Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
- May 11, 2020- Data shows reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began- Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT and Alinity i platforms and will have capacity for 60 million in June- Abbott expects to submit for CE Mark for its Alinity i SARS-CoV-2 IgG test this week and will initiate global shipments immediately- This is Abbott's fourth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic